English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Sansaar
    HomeNewsAurobindopharma

    Jump to
    • No scope of US intervention in Indian pharma cos: Wockhardt

      No scope of US intervention in Indian pharma cos: Wockhardt

      Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

    • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

      Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

      USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

    • US FDA completes Aurobindo's Unit 4 audit; to help boost US biz

      US FDA completes Aurobindo's Unit 4 audit; to help boost US biz

      Surajit Pal, Pharma Analyst at Prabhudas Lilladher told CNBC-TV18 that this is good news for Aurobindo as this plant has almost 26 percent of pending approvals which are important drivers for its US business.

    • Aurobindo's topline can swell by $350 m with Teva buy: PL

      Aurobindo's topline can swell by $350 m with Teva buy: PL

      Indian pharmaceutical companies Aurobindo and Intas are among the final contenders for Teva‘s generic drug business in UK. The strategy will help the companies expand their European business.

    • Lupin to see approvals after US FDA gives clean chit: Macquarie

      Lupin to see approvals after US FDA gives clean chit: Macquarie

      Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.

    • Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

      Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

      Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

    • 20% of Cipla FY17 revenues to come from US: Chirag Talati

      20% of Cipla FY17 revenues to come from US: Chirag Talati

      When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

    • Pharma cos facing pricing pressure in US: PhillipCap

      Pharma cos facing pricing pressure in US: PhillipCap

      In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

      Sun's margins may reduce to 30-32% post merger: Surajit Pal

      As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347